Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA Biosimilar HADLIMA (adalimumab-bwwd)
17.08.2022 - Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced the U.S. Food and Drug Administration (FDA) has approved the citrate-free, high-concentration (100 mg/mL) formulation of HADLIMA (adalimumab-bwwd), a biosimilar referencing ...